Skip to main content

Table 1 Characteristics of included studies

From: Anti-vascular endothelial growth factor for neovascular age-related macular degeneration: a meta-analysis of randomized controlled trials

Study

Location

Treatment groups

Followup, months

Number of patients

Age, years

VISION 2004 [6]

United States, Canada, Austria, Belgium, Czech Republic, Denmark, France, Germany, Hungary, Israel, Italy, the Netherlands, Poland, Portugal, Spain, Switzerland, UK, Brazil, Chile, Colombia, and Australia

Pegatanib and photocoagulation

12

904/304a

75/77a

ANCHOR 2006 [9]

United States, France, Germany, Hungary, Czech Republic, and Australia

Ranibizumab and photocoagulation

24

280/143b

76.7/77.8b

MARINA 2006 [10]

United States

Ranibizumab and photocoagulation

24

478/238b

77/77b

PIER 2008 [36]

United States

Ranibizumab and photocoagulation

24

121/63b

79/78b

ABC 2010 [34]

United Kingdom

Bevacizumab and photocoagulation

12

65/66c

79/81c

SACU 2009 [37]

Austria

Bevacizumab and photocoagulation

12

14/14c

78/78c

CATT 2011 [12]

United States

Bevacizumab and ranibizumab

24

586/599d

79.7/78.8d

IVAN 2013 [14]

United Kingdom

Bevacizumab and ranibizumab

24

296/314d

77.8/77.7d

GEFAL 2013 [35]

France

Bevacizumab and ranibizumab

12

191/183d

79.6/78.7d

MANTA 2013 [16]

Austria

Bevacizumab and ranibizumab

12

154/163d

76.7/77.6d

Subramanian 2010 [38]

United States

Bevacizumab and ranibizumab

12

15/7d

78/80d

Biswas 2011 [24]

India

Bevacizumab and ranibizumab

18

50/54d

64.4/63.5d

LUCAS 2015 [18]

Norway

Bevacizumab and ranibizumab

24

213/218d

62/78d

BRAMD 2016 [19]

Netherlands

Bevacizumab and ranibizumab

12

161/166d

79/78d

VIEW 1 [25]

United States and Canada

Aflibercept and ranibizumab

24

911/304e

78/78e

VIEW 2 [25]

Europe, the Middle East, Asia-Pacific, and Latin America

Aflibercept and ranibizumab

24

913/291e

74/73e

  1. aPregatanib group/photocoagulation group
  2. bRanibizumab group/photocoagulation group
  3. cBevacizumab group/photocoagulation group
  4. dBevacizumab group/ranibizumab group
  5. eAflibercept group/ranibizumab group